The short answer
Low and colleagues published the complete amino acid sequence of bovine thymosin beta-4 in the Proceedings of the National Academy of Sciences in February 1981, describing it as a thymic hormone. Its principal role as a G-actin sequestering protein was recognised later.
Key facts
- Publication
- PNAS, February 1981 (PMID 6940133)
- First author
- Low TL
- Source
- Bovine thymus
- Length
- 43 residues
- Original description
- Thymic hormone
- Later understanding
- G-actin sequestering protein
Where the name comes from
Thymosin refers to the thymus, the tissue the protein was isolated from. It was one of several thymic factors investigated in that era, when the thymus was a major focus of immunological research and preparations from it were expected to contain immune-regulating hormones.
What the 1981 paper reported
The complete amino acid sequence of the bovine protein: 43 residues, fully determined. Establishing a complete sequence in 1981 was substantial work, and it is what makes the paper a foundational reference rather than a preliminary report.
Research material referenced
TB-500 5mg, third-party HPLC tested
The framing that did not survive
It was described as a thymic hormone. That characterisation has not held: thymosin beta-4 is now understood principally as an intracellular actin-sequestering protein present in many cell types, not as a hormone secreted by the thymus to act elsewhere. This is a normal trajectory for a molecule named before its function was known, and the name outlasted the hypothesis.
Why the reframing matters
A hormone acts at a distance on cells bearing receptors for it. An intracellular actin-binding protein does not. The two imply completely different pharmacology, and the older framing lingers in secondary writing in ways that imply a signalling role the current understanding does not support.
From protein to fragment
TB-500 came much later, once the actin-binding activity had been localised to LKKTETQ and it became practical to synthesise the motif alone. The development code TB-500 belongs to that later phase, not to the 1981 work. That matters, because citing the discovery paper as a TB-500 reference attributes the fragment to research that predates it.
Frequently asked questions
Who discovered thymosin beta-4?
Low and colleagues published the complete bovine sequence in PNAS in February 1981.
Is it really a thymic hormone?
That was the original framing and it has not held. It is now understood principally as an intracellular G-actin sequestering protein found in many cell types.
Was TB-500 part of the 1981 work?
No. The fragment came later, once actin binding had been localised to the LKKTETQ motif.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedLow TL et al., Complete amino acid sequence of bovine thymosin beta 4. PNAS 1981 (PMID 6940133)pubmed.ncbi.nlm.nih.gov
- PubMedHannappel E, beta-Thymosins: Ann N Y Acad Sci 2007 (PMID 17468232)pubmed.ncbi.nlm.nih.gov
- PubMedErickson-Viitanen S et al., Distribution of thymosin beta 4 in vertebrate classes. Arch Biochem Biophys 1983 (PMID 6838210)pubmed.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al., Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- TB-500: Structure and Where It Comes FromSeven residues taken from the middle of a 43-residue protein, with an acetylated N-terminus. What that construction implies about its properties.
- TB-500 Molecular Structure and Physical Properties889.0 Da, C38H68N10O14, no cysteine or methionine, no aromatic residue. The physical consequences of a short, highly charged, flexible peptide.
- TB-500 Storage, Stability and ReconstitutionNo cysteine, methionine or asparagine, so the usual degradation routes do not apply. Adsorption to surfaces is the loss mechanism that actually matters.
- TB-500 Half-Life and ClearanceA seven-residue peptide with no half-life extension carries no protection against renal filtration or peptidases. Why acetylation helps only at one end.
- Cell Migration: What the Studies ReportMigration requires continual actin remodelling, which gives a sequestering protein a plausible route to affect it. What the assays measure and what they do not.